Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent, highly ...

Patients with immune thrombocytopenia (ITP) who received a first-in-class investigational drug in addition to standard ...

The addition of ianalumab to eltrombopag significantly improved outcomes for patients with pretreated primary immune ...

Ianalumab, which has already succeeded in testing against Sjogren’s syndrome, proved impactful in a condition that causes low ...

The novel agent, along with standard second-line therapy, may allow patients to stay off treatment for longer periods and may ...

A recent study reveals thrombocytopenia as a significant prognostic factor in low-risk MDS, impacting survival and treatment ...

Novartis is divulging details from ianalumab’s summertime | Novartis is divulging details from ianalumab’s phase 3 win in a rare autoimmune blood disorder, and the data suggest the treatment could del ...

Researchers led by investigators at Mass General Brigham have published valuable information about a rare but serious complication of anti-cancer immunotherapy, providing the first large-scale ...

Ianalumab, a monoclonal antibody, helped patients with immune thrombocytopenia (ITP) maintain safe platelet counts without ...

Novartis has reported positive outcomes from the VAYHIT2 Phase III trial assessing ianalumab plus eltrombopag to treat ...

An experimental monoclonal antibody called ianalumab had promising results for more than half of patients with primary immune thrombocytopenia enrolled in a phase 3 trial, according to data published ...

A late-breaking presentation at the American Society of Hematology (ASH) 2025 meeting revealed promising phase 3 findings for ...